Olmesartan Medoxomil 40mg + Amlodipine 5mg + Hydrochlorothiazide 12.5mg Tablet in PCD pharma franchise in Hyderabad

Olmesartan Medoxomil 40mg + Amlodipine 5mg + Hydrochlorothiazide 12.5mg Tablet in pharmaceutical manufacturing company in Mumbai

Olmesartan Medoxomil 40mg + Amlodipine 5mg + Hydrochlorothiazide 12.5mg Tablet in antihypertensive pharma franchise in Pune

Olmesartan Medoxomil 40mg + Amlodipine 5mg + Hydrochlorothiazide 12.5mg Tablet in pharma suppliers in Delhi

Olmesartan Medoxomil 40mg + Amlodipine 5mg + Hydrochlorothiazide 12.5mg Tablet in pharma export companies in Kolkata
Olmesartan Medoxomil 40mg + Amlodipine 5mg + Hydrochlorothiazide 12.5mg Tablet in pharma franchise opportunities in Bengaluru

Home/Products /olmesartan-medoxomil-40-mg-amlodipine-point-5-mg-tablet

Olmeslide AH 40 Tablet

Composition : Olmesartan medoxomil 40 mg + amlodipine 5 mg + hydrochlorothiazide 12.5 mg tablet

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹1/-

Olmetyle 40 AH Tablet is a fixed-dose combination of Olmesartan Medoxomil 40mg, Amlodipine 5mg, and Hydrochlorothiazide 12.5mg, formulated to effectively manage hypertension in patients requiring multi-drug therapy. Olmesartan is an angiotensin II receptor blocker (ARB) that lowers blood pressure by relaxing blood vessels. Amlodipine, a calcium channel blocker, enhances vasodilation and improves blood flow, while Hydrochlorothiazide is a thiazide diuretic that helps eliminate excess sodium and water, reducing overall blood volume. This triple combination offers a synergistic approach for patients with moderate to severe hypertension, ensuring better blood pressure control and reducing the risk of cardiovascular complications.

Read More

About the Product

Olmetyle 40 AH Tablet is a fixed-dose combination of Olmesartan Medoxomil 40mg, Amlodipine 5mg, and Hydrochlorothiazide 12.5mg, formulated to effectively manage hypertension in patients requiring multi-drug therapy. Olmesartan is an angiotensin II receptor blocker (ARB) that lowers blood pressure by relaxing blood vessels. Amlodipine, a calcium channel blocker, enhances vasodilation and improves blood flow, while Hydrochlorothiazide is a thiazide diuretic that helps eliminate excess sodium and water, reducing overall blood volume. This triple combination offers a synergistic approach for patients with moderate to severe hypertension, ensuring better blood pressure control and reducing the risk of cardiovascular complications.

Common side effects may include dizziness, headache, fatigue, swelling of ankles (due to amlodipine), increased urination, and electrolyte imbalance. Rare but serious side effects can include hypotension, kidney dysfunction, or allergic reactions. If any unusual symptoms occur, consult a physician immediately.

Olmetyle 40 AH Tablet is indicated for the management of essential hypertension, especially in patients who require a combination of an ARB, calcium channel blocker, and diuretic to achieve optimal blood pressure control. It may be prescribed when monotherapy or dual therapy is insufficient.

Use only as directed by a healthcare professional. Regular monitoring of blood pressure, kidney function, and electrolytes is essential during treatment. Not recommended during pregnancy. Patients should avoid abrupt discontinuation and should be advised to stay hydrated, especially in hot weather.

Store at a temperature below 30°C, away from moisture and direct sunlight. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation